Australia markets closed

Cue Biopharma, Inc. (CUE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
20.11-0.96 (-4.56%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5593.17M
Enterprise value 3519.33M
Trailing P/E N/A
Forward P/E 1-11.56
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)147.98
Price/book (mrq)7.35
Enterprise value/revenue 3129.56
Enterprise value/EBITDA 6-13.28

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3165.30%
S&P500 52-week change 317.36%
52-week high 331.69
52-week low 36.95
50-day moving average 321.62
200-day moving average 320.94

Share statistics

Avg vol (3-month) 3341.71k
Avg vol (10-day) 3219.77k
Shares outstanding 528.45M
Float 20.19M
% held by insiders 115.23%
% held by institutions 143.42%
Shares short (14 Jul 2020) 42.12M
Short ratio (14 Jul 2020) 44.88
Short % of float (14 Jul 2020) 47.69%
Short % of shares outstanding (14 Jul 2020) 47.44%
Shares short (prior month 14 Jun 2020) 4697.74k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)29 Jun 2020

Profitability

Profit margin 0.00%
Operating margin (ttm)-999.10%

Management effectiveness

Return on assets (ttm)-34.98%
Return on equity (ttm)-78.78%

Income statement

Revenue (ttm)4.01M
Revenue per share (ttm)0.16
Quarterly revenue growth (yoy)1.90%
Gross profit (ttm)-24.03M
EBITDA -39.11M
Net income avi to common (ttm)-39.56M
Diluted EPS (ttm)-1.56
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)84.93M
Total cash per share (mrq)2.88
Total debt (mrq)8.43M
Total debt/equity (mrq)10.52
Current ratio (mrq)5.95
Book value per share (mrq)2.73

Cash flow statement

Operating cash flow (ttm)-33.45M
Levered free cash flow (ttm)-16.52M